1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Anhui Fengyuan Pharmaceutical Co., Ltd Class A

Anhui Fengyuan Pharmaceutical Co., Ltd Class A

SSZSE:000153
5.59
CNY
+0.03
(+0.54%)
0.22EPS
21.68P/E
2.36BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3.65
3.89
3.59
4.65
5.89
6.79
7.4
7.6
8.36
9.02
9.2
9.22
8.3
7.51
Basic EPS, GAAP
0.07
0.09
0.08
0.1
0.15
0.14
0.18
0.24
0.28
0.35
0.34
0.35
0.21
0.23
Free Cash Flow per Basic Share
-0.44
-0.38
0.02
0.13
0.01
0.34
-0.18
0.23
0.24
0.81
0.22
-0.04
-0.22
- -
Dividend per Share
0.12
0.07
0.07
0.14
0.08
0.07
0.12
0.09
0.06
0.13
0.14
0.16
0.17
0.27
Book Value per Share
2.47
2.55
2.67
2.64
2.75
2.9
3.03
3.23
3.99
3.72
4.06
4.35
4.53
4.65
Tangible Book Value per Share
2.05
2.12
2.24
2.29
2.42
2.5
2.61
2.73
3.45
3.17
3.43
3.69
3.85
3.97
Basic Weighted Avg Shares
419
437
437
437
438
444
438
437
437
444
465
465
465
465
Sales/Revenue/Turnover
1,530
1,699
1,569
2,034
2,578
3,013
3,238
3,321
3,652
4,004
4,275
4,285
3,858
3,491
Operating Margin (%)
3.35
3.87
4.1
4.52
5.16
4.61
4.86
4.85
5.52
5.8
5.66
5.76
4.83
5.6
Depreciation Expense
59
69
64
69
75
75
71
71
115
122
126
128
148
- -
Net Income, GAAP
27
41
35
46
65
61
81
104
123
154
159
161
99
109
Effective Tax Rate (%)
33.93
27.09
25.31
31.32
32.41
34.79
32.79
26.08
26.26
25.38
26.8
24.47
24.27
19.73
Profit Margin (%)
1.79
2.41
2.24
2.25
2.53
2.02
2.5
3.12
3.37
3.86
3.73
3.75
2.58
3.11
Working Capital
266
9
-26
-71
6
-52
-296
-363
-70
-267
-111
-223
-280
-381
LT Debt
197
68
59
43
- -
- -
105
65
115
190
195
213
300
215
Total Equity
1,120
1,147
1,199
1,153
1,220
1,292
1,327
1,448
1,771
1,755
1,919
2,046
2,126
2,184
Return on Invested Capital (%)
1.4
2.06
1.48
-0.36
3.7
3.51
4.6
4.71
5.04
6.01
5.97
5.45
3.05
2.96
Return on Capital (%)
3.11
3.93
3.49
3.76
5.05
4.8
5.92
6.65
6.93
7.39
7.23
6.63
4.19
4.07
Return on Common Equity (%)
3.02
3.74
3.09
3.95
5.51
4.86
6.19
7.58
7.8
8.9
8.81
8.23
4.82
5.14

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
787
874
1,297
LT Borrowings
287
272
204
LT Finance Leases
13
11
11
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
465
465
465
Market Capitalization
2,914
3,048
2,356

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,096
2,348
2,089
Cash, Cash Equivalents & STI
387
471
480
Accounts Receivable, Net
990
1,056
943
Inventories
544
592
518
Total Current Liabilities
2,376
2,616
2,470
Payables & Accruals
- -
- -
- -
ST Debt
787
874
1,297
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.1%
8.25%
3.91%
Free Cash Flow
377.13%
105.14%
469.76%
Net Income, GAAP
13.71%
2.01%
-38.19%
Sales/Revenue/Turnover
9.99%
3.33%
-9.95%
Total Cash Common Dividend
20.31%
24.75%
12.46%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,121
1,187
954
1,023
4,285
2025
941
1,086
- -
733
3,858
2026
836
835
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.1
0.11
0.1
0.03
0.35
2025
0.08
0.08
- -
- -
0.21
2026
0.08
0.07
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.12
0.01
0.01
0.16
2025
0.02
0.12
- -
0.02
0.17
2026
0.02
0.12
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Tian Le Ru
Full Time Employees
4,278
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No.16 Dalian Road Hefei AN China 230051
IPO Date
Sep 20, 2000
Website
bbcayy.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Anhui Fengyuan Pharmaceutical Co., Ltd. (000153.SZ) researches, develops, produces, and sells a broad range of pharmaceutical products primarily in China, with exports to Africa, Southeast Asia, Central Asia, Europe, and other international markets. The company offers biopharmaceuticals, chemical pharmaceuticals, Chinese patent medicines, Chinese herbal decoction pieces, and active pharmaceutical ingredients (APIs), spanning categories such as gynecology, respiratory system, hormonal, antipyretic analgesic, mental health, antiviral, antibiotic, oral anesthetic, masks, urinary, water electrolyte balance, digestive system, cardiovascular, Yinpian, and nutrition and metabolism; key products include peritoneal dialysis solutions, electrolyte series, fructose series, fatty milk emulsions, amino acid series, ambroxol hydrochloride injections, isosorbide mononitrate injections, levofloxacin lactate injections, ibutilide fumarate injections, cilnidipine tablets, dexamethasone phosphate injections, oxytocin injections, and diclofenac sodium patches. Founded in 1997 and headquartered at No. 16 Dalian Road, Baohe Industrial Park, Hefei, Anhui Province, China, it operates as a high-tech enterprise and the first listed pharmaceutical company in Anhui Province, integrating R&D, manufacturing, and commercial distribution across multiple dosage forms and over 300 varieties. In recent developments, the company reported operating revenue growth in its Q3 2025 financials, with a strategic focus for 2025 on expanding core high-margin varieties, enhancing refined management for cost efficiency, accelerating new drug development, and increasing classic traditional Chinese medicine formulas to enrich its pipeline amid low current TCM revenue contribution of less than 1%. It continues to prioritize biopharmaceuticals, chemical drugs, and traditional Chinese medicines while pursuing operational efficiencies and product diversification.